← Back to Search

Other

225 mg BNC210 for Social Anxiety Disorder (PREVAIL Trial)

Phase 2
Waitlist Available
Research Sponsored by Bionomics Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights

PREVAIL Trial Summary

This trial is testing if a new drug can reduce anxiety during a speaking challenge, compared to a placebo, in people with social anxiety disorder.

Eligible Conditions
  • Social Anxiety Disorder

PREVAIL Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Subjective Units of Distress Scale (SUDS) - speaking challenge performance phase
Secondary outcome measures
Self-Statements During Public Speaking Scale (Negative Self-Statements subscale; SSPS-N)
State-Trait Anxiety Inventory (State component; STAI-State)
Subjective Units of Distress Scale (SUDS) - speaking challenge anticipation phase

PREVAIL Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 675 mg BNC210Experimental Treatment1 Intervention
Group II: 225 mg BNC210Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
225 mg BNC210
2022
Completed Phase 2
~160
675 mg BNC210
2022
Completed Phase 2
~160

Find a Location

Who is running the clinical trial?

Bionomics LimitedLead Sponsor
6 Previous Clinical Trials
619 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Other
Florida
New York
California
How old are they?
65+
18 - 65
What site did they apply to?
PREVAIL Study Clinical Trial Site
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

How responsive is this trial?

Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
2022. "A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05193409.
~48 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top